Industry News
Structure of key protein complex uncovered
Researchers at Memorial Sloan-Kettering Cancer Centre (MSKCC) in the USA have uncovered the structure of a network of proteins that help regulate the life cycle of cells. Understanding the network’s physical layout is an important step toward learning its function, and in finding ways to correct flaws in the system that could lead to cancer.
[ + ]FDA approves GroPep-based biopharma product
A biopharmaceutical product that uses GroPep's (ASX:GRO) cell culture products in its manufacturing process has received US Food and Drug Administration (FDA) regulatory approval. [ + ]
Domantis find expected to benefit Abbott
UK antibody therapeutics developer Domantis has pulled a double-headed rabbit out of the hat for its client, the big European pharma Abbott Laboratories. [ + ]
Genesis Biomed boosts advisory board, starts CEO hunt
Sydney-based Genesis Biomedical (ASX:GBL) is moving to raise its profile in the Australian biomedical marketplace, after appointing two more senior researchers to its new strategic advisory committee. [ + ]
XRT signs electron microscope deal with Gatan
Unlisted imaging company XRT, an investee of BioTech Capital (ASX:BTC), has entered a deal with Californian-based electron microscope accessory and software manufacturer Gatan to develop and distribute an x-ray microscope product for use with electron microscopes. [ + ]
New members named to biotech advisory council
Four new members have been appointed to the Australian Biotechnology Advisory Council (ABAC) -- the independent board of industry experts advising the government on biotech issues. [ + ]
We're out of start-up phase: Cryptome
Eighteen months after its AUD$6.6 million IPO in November 2003, Melbourne-based Cryptome Pharmaceuticals (ASX:CRP) has achieved all of the objectives listed in its IPO prospectus and claims that it is no longer in the start-up phase. [ + ]
Biosignal nets global contact lens deal
Sydney's Biosignal (ASX:BOS) and its partner, the Institute for Eye Research (IER), have closed a deal with an international contact lens manufacturer to develop anti-bacterial daily disposable and other frequent replacement contact lenses for eventual sale to the US and European markets. [ + ]
CSIRO robots team up with MIT
Australian robotics research has received some fresh input as a new partnership between the CSIRO and the MIT computer science and artificial intelligence laboratory in USA has been formed.
[ + ]Alchemia heartened by thumbs-up for Glaxo drug
Shares in Brisbane biopharma Alchemia (ASX:ACL) rose 7 per cent today on news that the US Food and Drug Administration has approved GlaxoSmithKline's anti-thrombotic drug Arixtra in surgical patients at high risk of life-threatening venous blood clots. [ + ]
AustCancer changes name, sets course for US
Oncology drug developer Australian Cancer Technology (ASX:ACU) has changed its name to Avantogen, and flagged its intention to relocate its headquarters to San Diego, on the US west coast, within a few years. [ + ]
Tissue Therapies patent accepted in Australia
The core patent for Tissue Therapies' (ASX:TIS) VitroGro growth factor complex, used to accelerate wound healing, has been accepted in Australia. [ + ]
Aust biotech posts three-year performance low: PwC
A new report on ASX-listed life sciences companies by PricewaterhouseCoopers shows that the sector has posted its worst quarterly performance in three years. [ + ]
Biotech pioneer BresaGen resurrected as service company
The dark clouds over venerable Adelaide biopharma BresaGen (ASX:BGN) have parted, revealing a little blue sky. But the resurrected company's business plan is focused on terra firma -- it is going back to its roots as a service company. [ + ]
Heraeus Noblelight acquires Spectral
Heraeus Noblelight has acquired the Spectral Technologies division of US company IST Corporation. IST Spectral Technologies is a manufacturer of light sources for analytical instrumentation.
[ + ]
